Pilot: Sunitinib Malate for Advance Ocular Disease of Von Hippel-Lindau Syndrome

试点：苹果酸舒尼替尼治疗冯希佩尔-林道综合征晚期眼部疾病

• 批准号: 7976049
• 负责人: DARBY THOMPSON
• 金额: $ 14.2万
• 依托单位: THE EMMES COMPANY, LLC
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-11-01 至 2011-10-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7976049
• 关键词: Pilot; Sunitinib; Malate; Advance; Ocular

Pilot Study of Sunitinib Malate for Advanced Ocular Disease of Von Hippel-Lindau Syndrome This study will determine if an experimental drug called sunitinib malate (Sutent) can help slow or stop the growth of eye angiomas (abnormal growth of blood vessels) in people with Von Hippel-Lindau (VHL) syndrome. VHL is a genetic disorder that increases production of body chemicals called vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF), which are important in the formation of new blood vessels.

苹果酸舒尼替尼治疗晚期眼病Von Hippel-Lindau综合征的初步研究 这项研究将确定一种名为苹果酸舒尼替尼（Sutent）的实验性药物是否可以帮助减缓或阻止Von Hippel-Lindau（VHL）综合征患者眼睛血管瘤（血管异常生长）的生长。VHL是一种遗传性疾病，会增加称为血管内皮生长因子（VEGF）和血小板衍生生长因子（PDGF）的体内化学物质的产生，这些化学物质在新血管的形成中很重要。